Biocept Q2 Revenues Skyrocket on Expanded Test Volume | GenomeWeb

NEW YORK (GenomeWeb) – Biocept reported today that its second quarter revenues increased more than seven times over year over year due to a jump in commercial test volume.

For the three months ended June 30, the San Diego-based liquid biopsy firm's total revenues rose to $662,860 from $76,768 in the prior year period. This included $596,000 in commercial assay revenues and $66,000 in development services test revenues.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genes involved in histone deacetylation in Arabidopsis, effects of pathogenic presenilin-1 mutations, and more.

After a study finds DNA from antibiotic-resistant bacteria in Beijing smog, residents there worry, according to the New York Times.

Canada begins its search for a chief government science advisor, Nature News reports.

A company is using facial recognition tools to identify genetic disorders from pictures, Technology Review reports.